Tibsovo Approval Is A Stepping Stone For Servier’s Longer-Term Oncology Strategy
Executive Summary
The privately held company expects five US FDA approvals by 2026 and will focus on big-ticket targets like immune checkpoints and cell therapies, CEO David K. Lee told Scrip.
You may also be interested in...
Tibsovo Gets A Win In AML Following Servier Takeover
Positive Phase III topline results follow the US FDA’s acceptance of the drug in cholangiocarcinoma and encouraging data in low-grade glioma at ASCO 2021.
ASCO Offers Glimpse Of LAG-3 Inhibitors’ Potential Opportunities – And Limitations
Clinical data released on drugs targeting LAG-3 from BMS, Regeneron, Merck & Co. and Immutep in a variety of cancers.
Agios Sells Cancer Portfolio To Servier To Focus On Genetic Diseases
Agios’ cellular metabolism expertise first delivered cancer drugs but sees greater opportunity in genetically defined diseases. CEO Jackie Fouse talked to Scrip about the business strategy.